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 STUDIES ON THE CELLULAR IMMUNE RESPONSE
IN PATIENTS WITH URINARY BLADDER CARCINOMA
VIII． ADCC ACTIVITY OF LYMPHOCYTES FROM PATIENTS
Shoichi NisHio， Shinichi IKEMoTo， Yukichi OZeNKi， SeiJi WADA，
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  Host resistance against malignant neoplasms is not clear in human tumor bearers． Many im－
munolDgical parameters are measured in patients with carcinoma， but these are usually not spe6ific
to the carcinoma．
  As a preliminary experiment for tumor specific assay， ADCC （antibody dependent cell－mediated
cytotoxicity） activity anq NPFC （natural plague forming cell） population were measured by means
of plaque formation of sheep red cells on a microplate．
  Twenty－six patients with urinary bladder carcinorna and 20 control subjects were examined．
Both ADCC activity and NPFC population were significantly depressed in patients group compared
with control subjects． Especially， the ADCC activity was very low in the high grade group ofpatients
whereas NPFC was lowest in the high stage group， but there was no difference between these two
groups concerning total hgst response （ADCC十NPFC）．
  We discuss about host resistance in patients with advanced urinary bladder carcinoma・
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1388 泌尿紀要28巻 II号 ig82年
尿道外傷，尿道カルンケル，膀胱結石，神経因性膀胱，
各1例）を選んだ．その平均年齢は59． 7歳であった。
 2） 方 法
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Fig． 1． Flow chart of ADCC assay
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Fig； 4． Comparison of NPFC population be－







Fig． 2． ’ Cbmparison of NPFC population
     between control subjects and ’pa－
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Fig． 5． Comparison of ADCC．’agti．vity ． betweep
    control subjects and patients with blad：
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Fig． 6． Comparison of ADCC activity between

















     low stage high stage
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F g． 7． Comparison of ADCC activity between
   low and high stage groups
Table 1． Comparison of ADCC／NPFC ratio in various groups











































































％，high grade群12．95％， low stage群16．42％，


































2） Nishio S， Morikawa Y， Horii A， Kawakita J，
 Nishijima T， Kishimoto T and Maekawa M：
 Studies on nonspecific cellular immune response
 in patients with urinary bladder carcinoma．








 出液を用いたLAI， LMI testについて．日工尿
 会誌70：305～31β，1979
5） Kodera Y and Michael AB： Antibody－dependent
 cell mediated cytotoxicity for human monolayer
 target cells bearing blood group and trans－
 plantation antigens for melanoma cells． lnt J
 Cancer 16： 579一一592， 1975
             （1982年6月29日受付）
